Breaking News Instant updates and real-time market news.

ADP

ADP

$116.02

0.14 (0.12%)

, DXC

DXC Technology

$95.93

1.28 (1.35%)

06:11
12/11/17
12/11
06:11
12/11/17
06:11

ADP upgraded to Buy from Neutral at Goldman Sachs

Goldman Sachs analyst James Schneider upgraded ADP (ADP) to Buy and raised his price target for the shares to $135 from $112. The stock closed Friday up 14c to $116.02. The analyst thinks the Street underestimates the company's margin expansion potential. He also expects its client retention to improve. Schneider calls ADP his top contrarian pick in Payments and IT Services for 2018. The analyst's top value pick is DXC Technology (DXC). His top "laggards picks" are FleetCor (FLT) and Wex (WEX). And his top large cap growth picks for 2018 are Visa (V) and MasterCard (MA).

ADP

ADP

$116.02

0.14 (0.12%)

DXC

DXC Technology

$95.93

1.28 (1.35%)

FLT

FleetCor

$186.43

0.71 (0.38%)

WEX

Wex

$128.25

-0.1 (-0.08%)

V

Visa

$112.60

1.2 (1.08%)

MA

MasterCard

$149.89

0.44 (0.29%)

  • 19

    Dec

ADP ADP
$116.02

0.14 (0.12%)

11/14/17
11/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Coca-Cola (KO) upgraded to Outperform from Market Perform at Wells Fargo with analyst Bonnie Herzog saying the shares should be a core holding in 2018 and beyond. 2. Deutsche Bank (DB) upgraded to Buy from Hold at HSBC with analyst Alevizos Alevizakos saying the current valuation seemingly ignores the upside inherent in the bank's improved capital position. 3. Famous Dave's (DAVE) upgraded to Buy from Hold at Craig-Hallum with analyst Alex Fuhrman citing the third quarter results beat, refranchising efforts progressing well and further G&A reductions targeted. 4. ADP (ADP) resumed at Equal Weight, up from Underweight, at Morgan Stanley with analyst Danyal Hussain saying he expects ADP to execute with a greater sense of urgency, but there is still "more work to do" and the proxy fight has put a spotlight on some concerns on which investors will remain focused, including margins and potential share losses, he tells investors. 5. Phoenix New Media (FENG) upgraded to Outperform from Neutral at Macquarie. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/17
MSCO
11/14/17
UPGRADE
Target $114
MSCO
Equal Weight
ADP resumed at Equal Weight, up from Underweight, at Morgan Stanley
Morgan Stanley analyst Danyal Hussain resumed coverage of ADP with an Equal Weight rating and $114 price target, up from the Underweight rating and $100 price target the firm had before it went to restricted on the stock. Following its recent proxy victory, Hussain expects ADP to execute with a greater sense of urgency, but there is still "more work to do" and the proxy fight has put a spotlight on some concerns on which investors will remain focused, including margins and potential share losses, he tells investors.
12/05/17
BOFA
12/05/17
UPGRADE
Target $131
BOFA
Buy
ADP upgraded to Buy on improved risk/reward at BofA/Merrill
BofA/Merrill analyst Jason Kupferberg upgraded ADP to Buy from Neutral and raised its price target to $131 from $116 based on improved risk/reward. Kupferberg expects an acceleration in second half 2018 operating metrics driven by increased sales force productivity and year-over-year comps, which will likely result in F19/20 P&L growth. The analyst believes the past quarter will prove to be a trough and anticipates operating margin expansion in the second half.
08/17/17
EVER
08/17/17
NO CHANGE
Target $115
EVER
In Line
ADP will have difficulty reaching Pershing's margin goal, says Evercore ISI
Evercore ISI analyst David Togut believes Pershing Square today made a "strong case" for EBIT margin expansion at ADP. The analyst, however, believes 1,200 basis points of EBIT margin expansion by fiscal year 2022 will be "very difficult to achieve." Togut keeps an In Line rating on ADP with a $115 price target.
DXC DXC Technology
$95.93

1.28 (1.35%)

11/16/17
JEFF
11/16/17
NO CHANGE
Target $86
JEFF
Buy
Jefferies ups PayPal target to $86, Square target to $47
After rolling forward his valuations to reflect 2019 estimates, Jefferies analyst Ramsey El-Assal raised his price target for PayPal (PYPL) to $86 from $80, for Square (SQ) to $47 from $44, for Visa (V) to $129 from $127 and for EPAM Systems (EPAM) to $118 from $115. He keeps Buy ratings on all four names. The analyst's top picks in Payments are First Data (FDC), FleetCor (FLT), PayPal and Wex (WEX). El-Assal's top picks in IT Services are Cognizant (CTSH) and DXC Technology (DXC).
11/13/17
RHCO
11/13/17
NO CHANGE
Target $100
RHCO
Hold
DXC Technology price target raised to $100 from $87 at SunTrust
SunTrust analyst Frank Atkins raised his price target on DXC Technology to $100 and kept his Hold rating following Q2 results. Atkins says the quarter showed continued progress on cost control as well as a significant impact from the transition of leases to capitalized from operating. The analyst adds that the company continues to make great strides in cost structure and drives higher EPS and profitability on a consistent basis.
11/13/17
JEFF
11/13/17
NO CHANGE
Target $44
JEFF
Buy
Jefferies raises price targets for Sqare, Green Dot and DXC
In a research note on the Payments, Processors & IT Services space, Jefferies analyst Ramsey El-Assal raised his price target for Square (SQ) to $44 from $38, for Green Dot (GDOT) to $73 from $63 and for DXC Technology (DXC) to $118 from $100. The analyst has Buy ratings on all three names.
11/13/17
KEYB
11/13/17
DOWNGRADE
KEYB
Sector Weight
FIS downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Arvind Ramnani downgraded FIS (FIS) to Sector Weight citing valuation with the shares up 22% year-to-date and a lack of catalysts. The analyst has higher conviction in DXC Technology (DXC) and EPAM Systems (EPAM).
FLT FleetCor
$186.43

0.71 (0.38%)

11/02/17
OPCO
11/02/17
NO CHANGE
Target $194
OPCO
Outperform
FleetCor price target raised to $194 from $185 at Oppenheimer
Oppenheimer analyst Glenn Greene raised his price target for FleetCor to $194 from $185 after the company reported solid Q3 results. The analyst reiterates an Outperform rating on the shares.
11/02/17
SBSH
11/02/17
NO CHANGE
Target $200
SBSH
Buy
FleetCor price target raised to $200 from $180 at Citi
Citi analyst Peter Christiansen raised his price target for FleetCor Technologies to $200 saying the company is "back on offense" following the better than expected quarter. The analyst keeps a Buy rating on the shares.
12/05/17
DBAB
12/05/17
NO CHANGE
Target $225
DBAB
Buy
Deutsche raises price targets for FleetCor, Wex
Deutsche Bank analyst Ashish Sabadra raised his price target for FleetCor Technologies (FLT) to $225 from $185 and for Wex (WEX) to $150 from $125. Organic growth acceleration along with margin expansion and capital allocations should drive 15%-20% earnings growth in 2018 for both companies, Sabadra tells investors in a research note on the fleet card space. The analyst also sees both FleetCor and Wex benefiting from U.S. tax reform. He has Buy ratings on both names.
WEX Wex
$128.25

-0.1 (-0.08%)

11/02/17
OPCO
11/02/17
NO CHANGE
Target $130
OPCO
Outperform
Wex price target raised to $130 from $120 at Oppenheimer
Oppenheimer analyst Glenn Greene raised his price target for Wex to $130 from $120 after the company reported solid Q3 results and raised its FY17 guidance. The analyst reiterates an Outperform rating on the shares.
10/17/17
RHCO
10/17/17
UPGRADE
Target $145
RHCO
Buy
Wex upgraded to Buy from Hold at SunTrust
SunTrust analyst Oscar Turner upgraded WEX to Buy from Hold and raised his price target to $145 from $110 to reflect more favorable risk-reward and expectations of strong execution in the core fleet business. Turner adds that higher fuel prices and lower than expected fraud losses are tailwinds that are not reflected in consensus.
V Visa
$112.60

1.2 (1.08%)

11/17/17
BOFA
11/17/17
NO CHANGE
BOFA
Buy
Visa highlights possible EC interchange changes, says BofA/Merrill
BofA Merrill Lynch analyst Jason Kupferberg said the "most interesting new disclosure" in Visa's (V) just-filed 10-K was that the European Commission may require the company to reduce its European cross-border interchange rates. The EC is focused specifically on interchange fees set by Visa and MasterCard (MA) that represent revenue for their card issuers, while their own network fees are not being looked at, Kupferberg noted. However, depending how much these interchange fees are potentially cut, he can't rule out "some type of downstream impact" on fees, he added. The analyst, who does not see any cause for concern about near-term estimates, recommends keeping a close eye on this issue. He keeps a Buy rating on Visa shares.
12/05/17
WEDB
12/05/17
NO CHANGE
WEDB
Visa, MasterCard 'most significant' beneficiaries of tax reform, says Wedbush
Wedbush analyst Moshe Katri says that now that the Senate and the House have voted to pass their respective tax reform bills, he believes there will be potential benefits for Visa (V) and MasterCard (MA), as they pay the majority of their taxes domestically and have large cash balances held offshore. A reduction in the corporate tax rate to 20% from 35% would be accretive to next year's adjusted EPS by roughly 5% to both companies, he adds. Furthermore, Katri argues that a lower rate for repatriating cash held abroad of 14%, could incentivize companies to bring cash back to the U.S., giving them ample balance sheet flexibility to distribute incremental cash to shareholders or for strategic deployment.
12/05/17
BARD
12/05/17
NO CHANGE
BARD
Outperform
Visa, MasterCard good ideas amid tech rotation, says Baird
Baird analyst David Koning said Visa (V) and MasterCard (MA) are two good ideas for investors as the market undergoes its rotation out of the tech sector. The analyst noted they are already nearing a five-year relative low and the shares could appreciate from there even if there was no change to the S&P P/E. Koning has an Outperform rating and $130 price target on Visa and an Outperform rating and $170 price target on MasterCard shares.
MA MasterCard
$149.89

0.44 (0.29%)

11/01/17
RHCO
11/01/17
NO CHANGE
Target $180
RHCO
Buy
MasterCard price target raised to $180 from $160 at SunTrust
SunTrust analyst Andrew Jeffrey raised his price target on MasterCard to $180 and kept his Buy rating after Q3 results. Jeffrey says improving global economy and market share gains in Europe will sustain MasterCard sales strength. The analyst also notes that the company's technology investments could weigh on margins but will position MasterCard for long-term growth in a rapidly changing Payments industry. Jeffrey adds that the company enjoys a first-mover and competitive advantage in B2B thanks to Vocalink and work on domestic fast ACH payments.

TODAY'S FREE FLY STORIES

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.